These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 30322476)

  • 1. Cognitive Impairment and Dementias.
    Khosravi M; Newberg A; Alavi A
    Semin Nucl Med; 2018 Nov; 48(6):498-512. PubMed ID: 30322476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Positron Emission Tomography-Based Assessment of Cognitive Impairment and Dementias, Critical Role of Fluorodeoxyglucose in such Settings.
    Newberg AB; Coble R; Khosravi M; Alavi A
    PET Clin; 2022 Jul; 17(3):479-494. PubMed ID: 35717103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain
    Nobili F; Arbizu J; Bouwman F; Drzezga A; Agosta F; Nestor P; Walker Z; Boccardi M;
    Eur J Neurol; 2018 Oct; 25(10):1201-1217. PubMed ID: 29932266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging in neurology: Alzheimer's and Parkinson's diseases.
    Sarikaya I
    Nucl Med Commun; 2015 Aug; 36(8):775-81. PubMed ID: 25920047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging and positron emission tomography in the diagnosis of neurodegenerative dementias.
    Del Sole A; Malaspina S; Magenta Biasina A
    Funct Neurol; 2016; 31(4):205-215. PubMed ID: 28072381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography imaging in dementia.
    Herholz K; Carter SF; Jones M
    Br J Radiol; 2007 Dec; 80 Spec No 2():S160-7. PubMed ID: 18445746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advancement and Clinical Implications of 18FDG-PET in Parkinson's Disease, Atypical Parkinsonisms, and Other Movement Disorders.
    Peralta C; Biafore F; Depetris TS; Bastianello M
    Curr Neurol Neurosci Rep; 2019 Jun; 19(8):56. PubMed ID: 31256288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dementia spectrum disorders: lessons learnt from decades with PET research.
    Wilson H; Pagano G; Politis M
    J Neural Transm (Vienna); 2019 Mar; 126(3):233-251. PubMed ID: 30762136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia.
    Cerami C; Della Rosa PA; Magnani G; Santangelo R; Marcone A; Cappa SF; Perani D
    Neuroimage Clin; 2015; 7():187-94. PubMed ID: 25610780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal PET Imaging of Amyloid and Tau Pathology in Alzheimer Disease and Non-Alzheimer Disease Dementias.
    Xia C; Dickerson BC
    PET Clin; 2017 Jul; 12(3):351-359. PubMed ID: 28576172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain fluorodeoxyglucose (FDG) PET in dementia.
    Kato T; Inui Y; Nakamura A; Ito K
    Ageing Res Rev; 2016 Sep; 30():73-84. PubMed ID: 26876244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of (18)FDG PET and (11)C-PIB PET brain imaging on the diagnosis of Alzheimer's disease and other dementias in a regional memory clinic in Hong Kong.
    Shea YF; Ha J; Lee SC; Chu LW
    Hong Kong Med J; 2016 Aug; 22(4):327-33. PubMed ID: 27313272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Cochrane review on brain [¹⁸F]FDG PET in dementia: limitations and future perspectives.
    Morbelli S; Garibotto V; Van De Giessen E; Arbizu J; Chételat G; Drezgza A; Hesse S; Lammertsma AA; Law I; Pappata' S; Payoux P; Pagani M;
    Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1487-91. PubMed ID: 26067090
    [No Abstract]   [Full Text] [Related]  

  • 17. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review.
    Petrou M; Dwamena BA; Foerster BR; MacEachern MP; Bohnen NI; Müller ML; Albin RL; Frey KA
    Mov Disord; 2015 Jun; 30(7):928-35. PubMed ID: 25879534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice.
    Atri A
    Handb Clin Neurol; 2016; 136():971-84. PubMed ID: 27430453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Added value and limitations of amyloid-PET imaging: review and analysis of selected cases of mild cognitive impairment and dementia.
    Weidman DA; Zamrini E; Sabbagh MN; Jacobson S; Burke A; Belden C; Powell J; Bhalla N; Roontiva A; Kuang X; Luo J; Chen K; Riggs G; Burke W
    Neurocase; 2017 Feb; 23(1):41-51. PubMed ID: 28376695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
    Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
    J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.